FDA approves first vaccine to protect infants from RSV
Respiratory Syncytial Virus Vaccine Approved for Infants
The US Food and Drug Administration (FDA) 21 August 2023 announced its approval for the use of Pfizer’s new respiratory syncytial virus (RSV) vaccine in pregnant women and to help protect infants as old as 6 months old. This vaccine is marking a new way to protect babies. A group that is at higher risk for complications from the virus.
FDA’s approval is for use of the vaccine at 32 to 36 weeks gestational age of pregnancy. The vaccine, called Abrysvo, is administered as a single intramuscular dose. Pregnant women in this latter stage of pregnancy are the second group approved to receive Abrysvo. In May, the FDA cleared the vaccine for use in adults ages 60 and older.